跳至主要内容
临床试验/ACTRN12608000052336
ACTRN12608000052336尚未招募1 期

A Prospective, Randomized, Controlled, Pilot Clinical Study to Evaluate GEMOS2 (ß-TCP/collagen matrix combined with rhPDGF-BB) for the Treatment of Unstable Distal Radius Fractures

BioMimetics Therapeutics Inc0 个研究点目标入组 20 人开始时间: 2008年1月29日最近更新:

试验速览

阶段
1 期
状态
尚未招募
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Subjects who meet the following criteria may be included in the study if they present with all of
  • the following:
  • 1) The subject has signed the Independent Ethics Committee (IEC) approved Informed
  • Consent Form specific to this study prior to enrollment
  • 2) The subject has an unstable unilateral, extraarticular distal radius fracture classified as
  • unstable with the following radiographic findings: wide displacement requiring reduction
  • defined as >10° or 20° volar tilt or instability defined as 20° dorsal tilt; or an intraarticular
  • fracture that is amenable to external-fixation or closed fracture reduction.
  • Avulsed ulnar styloid tip is allowed
  • 3) The subject’s fracture is able to be manually reduced in a single attempt up to 2 weeks
  • post injury
  • 4) The subject is independent, ambulatory, and can comply with all post-treatment
  • evaluations and visits
  • 5) The subject is skeletally mature and =18 years of age
  • 6) The distal radius fracture does not require structural bone graft.

排除标准

  • Subjects will be excluded from the study if they present with any of the following:
  • 1) The subject has suffered a previous wrist fracture on the affected wrist or contralateral
  • wrist within the previous 12 months of the current fracture date
  • 2) The subject’s fracture meets any of the following criteria:
  • Bilateral distal radius fractures or clinically significant injury to the contralateral limb.
  • Severe comminution involving the diaphysis of the radius and/or radioulnar joint.
  • Ulnar fracture (AO: A1.1, A1.2, and A1.3)
  • Presence of pre-operative hard or soft tissue infection at the operative site.
  • Requires supplemental internal fixation for adequate reduction (e.g. plates)
  • Open fractures
  • Closed head injuries
  • Intra-articular fracture with diastasis of the subchondral bone
  • 3) The subject is currently undergoing radiotherapy or chemotherapy
  • 4) The subject has a metabolic disorder known to adversely affect the skeleton, other than primary osteoporosis (e.g., renal osteodystrophy)
  • 5) The subject uses chronic medications known to affect the skeleton (e.g. glucocorticoid usage > 10mg/day). Note: NSAID use is excluded during the first 6 weeks post-treatment
  • 6) The subject has a clotting disorder or uses anticoagulant therapy (e.g., coumadin). Antiplatelet therapy is acceptable for daily cardiovascular maintenance
  • 7) The subject has a pre-fracture neuromuscular or musculoskeletal deficiency which limits the ability to perform objective functional measurements
  • 8) The subject is physically or mentally compromised (e.g., currently being treated for a psychiatric disorder, senile dementia, Alzheimer’s disease, etc.)
  • 9) The subject has an allergy to yeast-derived products
  • 10) Allergy to bovine collagen and/or to other bovine source medication, supplements or products
  • 11) The subject is enrolled in another device or drug investigational study (currently or within the past 30 days of surgery or during the follow-up phase of this study)
  • 12) The subject is a prisoner, is known or suspected to be transient, or has a history of drug/alcohol abuse (as determined by investigator) within the 12 months prior to screening for study entry
  • 13) The subject is pregnant or a female intending to become pregnant during this study period.

研究者

发起方
BioMimetics Therapeutics Inc

相似试验